Trial Profile

A Single-center, Prospective, Single-arm Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; Pemetrexed (Primary) ; Toripalimab (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms Renaissance

Most Recent Events

24 Oct 2023 Results assessing efficacy and safety of neoadjuvant toripalimab plus chemotherapy for resectable stage IIB-IIIB NSCLC, presented at the 48th European Society for Medical Oncology Congress.
31 Mar 2023 Study phase changed from Phase 1/2 to Phase 2. Primary and secondary outcome measures amended. Safety endpoints removed from primary endpoints.
31 Mar 2023 Planned number of patients changed from 75 to 100.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com